drugset / Trial / NCT07212088
Stereotactic Intracerebral Injection of Allogenic IPSC-DAPs in Patients With Parkinson's Disease
Phase 1
Not yet recruiting
12 enrolled
iCamuno Biotherapeutics Ltd.
Second Affiliated Hospital, School of Medicine, Zhejiang University · collab
RandomizedParallel-groupOpen-labelTreatment
Summary
Parkinson's disease is a progressive neurodegenerative disorder characterized by high morbidity due to the limited regenerative capacity of dopaminergic neurons in the brain. Current drug treatments primarily manage symptoms but do not halt or reverse neuronal loss. Cellular replacement therapy has emerged as a potential strategy to restore dopaminergic function and address the underlying neuronal deficits. This study aims to evaluate the safety, feasibility, and efficacy of transplanting dopaminergic neurons into the brain to improve motor function and quality of life in patients with advanced Parkinson's disease.
Timeline
- Start
- 2026-02-28
- Primary completion
- 2027-12-15
- Completion
- 2028-06-15
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | ALC01 | Cell therapy | — | Other |